摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Cyclopentyl-7-{4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]phenylamino}pyrimido[4,5-d]pyrimidin-2(1H)-one | 251369-85-4

中文名称
——
中文别名
——
英文名称
1-Cyclopentyl-7-{4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]phenylamino}pyrimido[4,5-d]pyrimidin-2(1H)-one
英文别名
1-Cyclopentyl-7-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]pyrimido[4,5-d]pyrimidin-2-one
1-Cyclopentyl-7-{4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]phenylamino}pyrimido[4,5-d]pyrimidin-2(1H)-one化学式
CAS
251369-85-4
化学式
C29H39N7O2
mdl
——
分子量
517.674
InChiKey
MAFLMDDLVBFCJM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    38
  • 可旋转键数:
    8
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    86.2
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
    申请人:——
    公开号:US20040044012A1
    公开(公告)日:2004-03-04
    This invention provides bicyclic heterocycles that are useful for treating cell proliferative disorders, such as cancer and restenosis, as well as angiogenesis and atherosclerosis. We have now discovered a group of bicyclic compounds that are potent inhibitors of cyclin-dependent kinases (cdks), growth factor-mediated kinases, and non-receptor kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability for clinical use. This invention provides compounds of Formula I: 1 where Z is N or CH; G is N or CH; W is NH, S, SO, or SO 2 , R 1 includes phenyl and substituted phenyl, R 2 includes alkyl and cycloalkyl, R 3 includes alkyl and hydrogen, R 8 and R 9 include hydrogen and alkyl, and the pharmaceutically acceptable salts thereof. This invention also provides pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.
    本发明提供了一种双环杂环化合物,用于治疗细胞增殖紊乱,如癌症和再狭窄,以及血管生成和动脉粥样硬化。我们已经发现了一组双环化合物,它们是周期蛋白依赖性激酶(cdks)、生长因子介导的激酶和非受体激酶的强效抑制剂。这些化合物易于合成,可以通过包括口服在内的多种途径给药,并且具有足够的生物利用度,适用于临床使用。本发明提供的化合物如公式I所示: 1 其中 Z是N或CH; G是N或CH; W是NH、S、SO或SO2; R1包括苯基和取代苯基, R2包括烷基和环烷基, R3包括烷基和氢, R8和R9包括氢和烷基,以及药用可接受的盐。 本发明还提供了包含公式I化合物的药物制剂,以及药用可接受的载体、稀释剂或辅料。
  • BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION
    申请人:Warner-Lambert Company LLC
    公开号:EP1080092B1
    公开(公告)日:2008-07-23
  • US7501425B1
    申请人:——
    公开号:US7501425B1
    公开(公告)日:2009-03-10
查看更多